These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

184 related articles for article (PubMed ID: 38194777)

  • 1. An overview of the functions of p53 and drugs acting either on wild- or mutant-type p53.
    Huang Y; Jiao Z; Fu Y; Hou Y; Sun J; Hu F; Yu S; Gong K; Liu Y; Zhao G
    Eur J Med Chem; 2024 Feb; 265():116121. PubMed ID: 38194777
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Unraveling the Role of
    Li W; Li L; Yang H; Shi C; Lei Z; Guo L; Wang Y
    Front Biosci (Landmark Ed); 2024 Jul; 29(7):272. PubMed ID: 39082342
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Advanced Strategies for Therapeutic Targeting of Wild-Type and Mutant p53 in Cancer.
    Zhang S; Carlsen L; Hernandez Borrero L; Seyhan AA; Tian X; El-Deiry WS
    Biomolecules; 2022 Apr; 12(4):. PubMed ID: 35454137
    [No Abstract]   [Full Text] [Related]  

  • 4. Recent advances in p53 research and cancer treatment.
    Suzuki K; Matsubara H
    J Biomed Biotechnol; 2011; 2011():978312. PubMed ID: 21765642
    [TBL] [Abstract][Full Text] [Related]  

  • 5. Wild type- and mutant p53 proteins in mitochondrial dysfunction: emerging insights in cancer disease.
    Blandino G; Valenti F; Sacconi A; Di Agostino S
    Semin Cell Dev Biol; 2020 Feb; 98():105-117. PubMed ID: 31112799
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Should mutant TP53 be targeted for cancer therapy?
    Wang Z; Strasser A; Kelly GL
    Cell Death Differ; 2022 May; 29(5):911-920. PubMed ID: 35332311
    [TBL] [Abstract][Full Text] [Related]  

  • 7. New therapeutic strategies to treat human cancers expressing mutant p53 proteins.
    Blandino G; Di Agostino S
    J Exp Clin Cancer Res; 2018 Feb; 37(1):30. PubMed ID: 29448954
    [TBL] [Abstract][Full Text] [Related]  

  • 8. Effects of TP53 mutational status on gene expression patterns across 10 human cancer types.
    Parikh N; Hilsenbeck S; Creighton CJ; Dayaram T; Shuck R; Shinbrot E; Xi L; Gibbs RA; Wheeler DA; Donehower LA
    J Pathol; 2014 Apr; 232(5):522-33. PubMed ID: 24374933
    [TBL] [Abstract][Full Text] [Related]  

  • 9. [TP53 mutations and molecular epidemiology].
    Otsuka K; Ishioka C
    Gan To Kagaku Ryoho; 2007 May; 34(5):683-9. PubMed ID: 17496437
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Targeting mutant p53 for efficient cancer therapy.
    Bykov VJN; Eriksson SE; Bianchi J; Wiman KG
    Nat Rev Cancer; 2018 Feb; 18(2):89-102. PubMed ID: 29242642
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Mutant p53: it's not all one and the same.
    Kennedy MC; Lowe SW
    Cell Death Differ; 2022 May; 29(5):983-987. PubMed ID: 35361963
    [TBL] [Abstract][Full Text] [Related]  

  • 12. MicroRNA-Mutant P53 Crosstalk in Chemoresistance: A Hint to Monitor Therapy Outcome.
    Speciale A; Monti P; Fronza G; Izzotti A; Menichini P
    Microrna; 2020; 9(5):322-335. PubMed ID: 33297928
    [TBL] [Abstract][Full Text] [Related]  

  • 13. p53 mutant-type in human prostate cancer cells determines the sensitivity to phenethyl isothiocyanate induced growth inhibition.
    Aggarwal M; Saxena R; Asif N; Sinclair E; Tan J; Cruz I; Berry D; Kallakury B; Pham Q; Wang TTY; Chung FL
    J Exp Clin Cancer Res; 2019 Jul; 38(1):307. PubMed ID: 31307507
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Therapeutic potential of combating cancer by restoring wild-type p53 through mRNA nanodelivery.
    Kamath D; Iwakuma T; Bossmann SH
    Nanomedicine; 2024 Feb; 56():102732. PubMed ID: 38199451
    [TBL] [Abstract][Full Text] [Related]  

  • 15. p53 in breast cancer subtypes and new insights into response to chemotherapy.
    Bertheau P; Lehmann-Che J; Varna M; Dumay A; Poirot B; Porcher R; Turpin E; Plassa LF; de Roquancourt A; Bourstyn E; de Cremoux P; Janin A; Giacchetti S; Espié M; de Thé H
    Breast; 2013 Aug; 22 Suppl 2():S27-9. PubMed ID: 24074787
    [TBL] [Abstract][Full Text] [Related]  

  • 16.
    Di-Iacovo N; Ferracchiato S; Pieroni S; Scopetti D; Castelli M; Piobbico D; Pierucci L; Gargaro M; Chiasserini D; Servillo G; Della-Fazia MA
    Int J Mol Sci; 2024 Apr; 25(9):. PubMed ID: 38731819
    [No Abstract]   [Full Text] [Related]  

  • 17. Functional characterisation of p53 mutants identified in breast cancers with suboptimal responses to anthracyclines or mitomycin.
    Berge EO; Huun J; Lillehaug JR; Lønning PE; Knappskog S
    Biochim Biophys Acta; 2013 Mar; 1830(3):2790-7. PubMed ID: 23246812
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Awakening the "guardian of genome": reactivation of mutant p53.
    Binayke A; Mishra S; Suman P; Das S; Chander H
    Cancer Chemother Pharmacol; 2019 Jan; 83(1):1-15. PubMed ID: 30324219
    [TBL] [Abstract][Full Text] [Related]  

  • 19. The dual role of mutant p53 protein in chemosensitivity of human cancers.
    Mueller H; Eppenberger U
    Anticancer Res; 1996; 16(6B):3845-8. PubMed ID: 9042268
    [TBL] [Abstract][Full Text] [Related]  

  • 20. How mutations shape p53 interactions with the genome to promote tumorigenesis and drug resistance.
    Stiewe T; Haran TE
    Drug Resist Updat; 2018 May; 38():27-43. PubMed ID: 29857816
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 10.